<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590496</url>
  </required_header>
  <id_info>
    <org_study_id>PROPER-LDL Trial</org_study_id>
    <nct_id>NCT03590496</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Propionate for Reduction of LDL Cholesterol</brief_title>
  <acronym>PROPER-LDL</acronym>
  <official_title>Safety and Efficacy of PROPionatE for Reduction of LDL Cholesterol (PROPER-LDL Trial) - A Phase 2 Randomized Placebo Controlled Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to evaluate a potential impact of food supplements with the
      short chain fatty acid propionate on blood LDL cholesterol level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      124 patients with hypercholesterolemia (LDL serum level &gt; 115 mg/dl) will be enrolled. 62
      patients with moderate cardiovascular risk will be 1:1 randomized to receive either Placebo
      (b.i.d.) or 500mg of propionate (b.i.d.) in addition to their basic cholesterol lowering
      treatment with 10mg Atorvastatin per day. Another 62 patients with low cardiovascular risk
      will be 1:1 randomized to receive either placebo (b.i.d.) or 500mg of propionate (b.i.d.).
      The primary endpoint is the change (delta) in blood LDL cholesterol levels after 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-cholesterol reduction</measure>
    <time_frame>8 weeks</time_frame>
    <description>mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total cholesterol</measure>
    <time_frame>8 weeks</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-cholesterol</measure>
    <time_frame>8 weeks</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non HDL</measure>
    <time_frame>8 weeks</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio HDL/LDL</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>31 patients will be treated with 500mg Calcium-Propionate capsules (twice a day) in addition to their basic cholesterol lowering therapy with 10mg Atorvastatin (once per day) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>31 patients will be treated with placebo capsules (twice a day) in addition to their basic cholesterol lowering therapy with 10mg Atorvastatin (once per day) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>31 patients will be treated with 500mg Calcium-Propionate capsules (twice a day) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>31 patients will be treated with placebo capsules (twice a day) for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 10mg</intervention_name>
    <description>Atorvastatin-Calcium Film-coated tablets</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium-Propionate 500mg</intervention_name>
    <description>Calcium-Propionate capsules</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules without any active ingredient</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with hypercholestrolemia and a LDL serum level of &gt; 115 mg/dl

          -  age of patient between 20 and 70 years

          -  participant is fully competent and has given his/her written informed consent to the
             scheduled trial conduct

        Exclusion Criteria:

          -  patients with acute coronary syndrome in the last 4 weeks

          -  patients with chronic symptomatic heart failure (NYHA 2-4)

          -  patients with chronic renal failure and a GFR &lt; 45 ml/min

          -  patients with chronic liver disease

          -  patients with hematological diseases

          -  patients with severe diseases of other organ systems (tumors, infections)

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arash Haghikia, PD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arash Haghikia, PD MD</last_name>
    <phone>(0)30450513797</phone>
    <phone_ext>+49</phone_ext>
    <email>arash.haghikia@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Schumann, PhD candidate</last_name>
    <phone>(0)30450513807</phone>
    <phone_ext>+49</phone_ext>
    <email>paul.schumann@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Josef-hospital Ruhr-Univesity Bochum</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christos Krogias, PD MD</last_name>
      <phone>+492345092411</phone>
      <email>christos.krogias@ruhr-uni-bochum.de</email>
    </contact>
    <investigator>
      <last_name>Christos Krogias, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arash Haghikia, PD MD</last_name>
      <phone>(0)30450513797</phone>
      <phone_ext>+49</phone_ext>
      <email>arash.haghikia@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Paul Schumann</last_name>
      <phone>(0)30450513807</phone>
      <phone_ext>+49</phone_ext>
      <email>paul.schumann@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Arash Haghikia, PD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Friederike Zimmermann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJ, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sanchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Diaz R, Lonn E; HOPE-3 Investigators. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016 May 26;374(21):2021-31. doi: 10.1056/NEJMoa1600176. Epub 2016 Apr 2.</citation>
    <PMID>27040132</PMID>
  </reference>
  <reference>
    <citation>Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.</citation>
    <PMID>26039521</PMID>
  </reference>
  <reference>
    <citation>Kataoka Y, St John J, Wolski K, Uno K, Puri R, Tuzcu EM, Nissen SE, Nicholls SJ. Atheroma progression in hyporesponders to statin therapy. Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):990-5. doi: 10.1161/ATVBAHA.114.304477. Epub 2015 Feb 26.</citation>
    <PMID>25722430</PMID>
  </reference>
  <reference>
    <citation>Berggren AM, Nyman EM, Lundquist I, Björck IM. Influence of orally and rectally administered propionate on cholesterol and glucose metabolism in obese rats. Br J Nutr. 1996 Aug;76(2):287-94.</citation>
    <PMID>8813902</PMID>
  </reference>
  <reference>
    <citation>Lu Y, Fan C, Li P, Lu Y, Chang X, Qi K. Short Chain Fatty Acids Prevent High-fat-diet-induced Obesity in Mice by Regulating G Protein-coupled Receptors and Gut Microbiota. Sci Rep. 2016 Nov 28;6:37589. doi: 10.1038/srep37589.</citation>
    <PMID>27892486</PMID>
  </reference>
  <reference>
    <citation>Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese SE, MacDougall K, Preston T, Tedford C, Finlayson GS, Blundell JE, Bell JD, Thomas EL, Mt-Isa S, Ashby D, Gibson GR, Kolida S, Dhillo WS, Bloom SR, Morley W, Clegg S, Frost G. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. 2015 Nov;64(11):1744-54. doi: 10.1136/gutjnl-2014-307913. Epub 2014 Dec 10.</citation>
    <PMID>25500202</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 6, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>September 4, 2018</last_update_submitted>
  <last_update_submitted_qc>September 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Arash Haghikia</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>propionate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

